股市必读：金陵药业（000919）9月10日董秘有最新回复

Core Viewpoint - Jinling Pharmaceutical (000919) is experiencing a decline in stock price and facing challenges in its medical service segment, which now accounts for over 50% of its revenue, while industry classification remains inconsistent among different financial platforms [1][2]. Group 1: Stock Performance - As of September 10, 2025, Jinling Pharmaceutical's stock closed at 7.2 yuan, down 0.28% with a turnover rate of 1.15% [1]. - The trading volume was 67,900 shares, resulting in a transaction amount of 48.91 million yuan [1]. Group 2: Industry Classification - The company is classified differently by various financial institutions; it is categorized as part of the chemical pharmaceutical industry by Tonghuashun and as part of the traditional Chinese medicine industry by Dongfang Caifu, while the official classification by the China Securities Regulatory Commission lists it under the pharmaceutical manufacturing industry [2]. Group 3: Financial Performance and Comparison - Jinling Pharmaceutical's subsidiary, Suqian Hospital, has seen stagnant revenue and declining profits, contrasting with Xi'an Gaoxin Hospital under International Medical, which has experienced continuous growth in both revenue and profits [2]. Group 4: Capital Flow - On September 10, 2025, there was a net outflow of 4.702 million yuan from institutional investors and a net outflow of 2.1691 million yuan from speculative funds, while retail investors saw a net inflow of 6.8711 million yuan [3].